Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Director William R. Ringo sold 500 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $46.73, for a total transaction of $23,365.00. Following the sale, the director now owns 500 shares in the company, valued at approximately $23,365. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) traded down 1.54% during midday trading on Monday, reaching $41.62. 27,235 shares of the company traded hands. The company’s market capitalization is $1.14 billion. The company has a 50 day moving average price of $45.83 and a 200 day moving average price of $49.81. Five Prime Therapeutics, Inc. has a 1-year low of $30.35 and a 1-year high of $60.98.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Thursday, February 23rd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.16. Five Prime Therapeutics had a return on equity of 59.23% and a net margin of 64.94%. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $7.09 million. During the same period last year, the company posted $10.63 earnings per share. The business’s quarterly revenue was down 97.7% on a year-over-year basis. On average, analysts expect that Five Prime Therapeutics, Inc. will post ($4.47) earnings per share for the current year.
FPRX has been the topic of a number of recent analyst reports. Jefferies Group LLC set a $60.00 price target on shares of Five Prime Therapeutics and gave the company a “buy” rating in a report on Friday, December 9th. Nomura initiated coverage on shares of Five Prime Therapeutics in a report on Wednesday, March 1st. They set a “buy” rating on the stock. Instinet initiated coverage on shares of Five Prime Therapeutics in a report on Wednesday, March 1st. They set a “buy” rating and a $94.00 price target on the stock. Finally, Credit Suisse Group AG reiterated a “buy” rating and set a $54.00 price target on shares of Five Prime Therapeutics in a report on Monday, November 7th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $59.38.
A number of hedge funds have recently made changes to their positions in the company. ARK Investment Management LLC purchased a new position in Five Prime Therapeutics during the fourth quarter valued at $160,000. Legal & General Group Plc boosted its position in Five Prime Therapeutics by 5.4% in the second quarter. Legal & General Group Plc now owns 4,077 shares of the company’s stock valued at $169,000 after buying an additional 208 shares during the last quarter. Suntrust Banks Inc. purchased a new position in Five Prime Therapeutics during the third quarter valued at $219,000. Franklin Street Advisors Inc. NC purchased a new position in Five Prime Therapeutics during the third quarter valued at $262,000. Finally, WCM Investment Management CA purchased a new position in Five Prime Therapeutics during the third quarter valued at $286,000. 93.38% of the stock is currently owned by hedge funds and other institutional investors.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.